Triamcinolone–moxifloxacin combo prevents macular edema in diabetic retinopathy after cataract surgery

Clinically significant macular oedema (CSMO) present at the time of cataract surgery is likely to progress and eyes with previously treated CSMO are at increased risk of recurrence. The risk of progression is increased if the operation is complicated by excessive manipulation, vitreous loss, or severe post-operative inflammation.

Researchers evaluated the effect of intravitreal triamcinolone acetonide–moxifloxacin at the time of cataract surgery on central macular edema in patients with preexisting diabetic retinopathy.

The retrospective chart review included 75 eyes of 64 patients who had undergone recent cataract surgery. Intravitreal injection of triamcinolone–moxifloxacin was given at the time of surgery.

"We aimed to record the visual acuity and central macular thickness (CMT) with optical coherence tomography at preoperative and postoperative visits," says Julia Angkadjaja, MD, Loma Linda University Eye Institute, Loma Linda University Health, Loma Linda, California, USA.

Hence, the authors drew the following results-

a. Mean visual acuity at 4 to 6 weeks, 6 to 12 weeks, and 12 weeks or more postoperatively was 0.32, 0.35, and 0.43, respectively.

b. Mean CMT 4 to 6 weeks postoperatively for 46 eyes decreased from 299 μm to 297 μm.

c. Mean CMT 6 to 12 weeks postoperatively for 34 eyes increased from 317 μm to 344 μm.

d. Mean CMT 12 weeks or more for 60 eyes increased from 295 μm to 328 μm.

As a result, the conclusion was the "Intravitreal triamcinolone acetonide–moxifloxacin at the time of cataract surgery for patients with diabetic retinopathy maintained stable central macular thickness in the postoperative period, most notably in the 4- to 6-week period."

For the full article click on the link: 10.1097/j.jcrs.000000000000024